Pharsight

Acuvail patents expiration

ACUVAIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7842714 ABBVIE Ketorolac tromethamine compositions for treating ocular pain
Aug, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952 ABBVIE Compositions for delivery of therapeutics into the eyes and methods for making and using same
Aug, 2024

(a month from now)

US8512717 ABBVIE Compositions for delivery of therapeutics into the eyes and methods for making and using same
Mar, 2028

(3 years from now)

US9192571 ABBVIE Ketorolac tromethamine compositions for treating or preventing ocular pain
Mar, 2028

(3 years from now)

Acuvail is owned by Abbvie.

Acuvail contains Ketorolac Tromethamine.

Acuvail has a total of 4 drug patents out of which 0 drug patents have expired.

Acuvail was authorised for market use on 22 July, 2009.

Acuvail is available in solution/drops;ophthalmic dosage forms.

The generics of Acuvail are possible to be released after 15 August, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 22, 2012

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage

ACUVAIL family patents

Family Patents